Correlation analysis of low expression of LY86-AS1 and KHDRBS2 with immune cell invasion and prognosis in glioblastoma.
- Author:
Shasha WANG
1
;
Wenhao ZHAO
2
;
Xining HE
2
;
Yangyang ZHANG
1
;
Wenli CHANG
3
,
4
Author Information
1. Department of Pathology, Affiliated Hospital of Binzhou Medical University, Binzhou 256600, China.
2. Department of Neurosurgery, Affiliated Binzhou People's Hospital, Shandong First Medical University, Binzhou 256600, China.
3. Department of Pathology, Affiliated Hospital of Binzhou Medical University, Binzhou 256600, China. *Corresponding author, E-mail: wenli_075010768@
4. com.
- Publication Type:Journal Article
- MeSH:
Humans;
Glioblastoma/metabolism*;
Prognosis;
Brain Neoplasms/pathology*;
Gene Expression Regulation, Neoplastic;
RNA-Binding Proteins/metabolism*
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(3):245-253
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the expression and correlation of LY86-AS1 and KHDRBS2 in glioblastoma (GBM), and their impacts on the prognosis of patients and immune cell infiltration. Methods Based on the GSE50161 dataset from the Gene Expression Omnibus (GEO) database, LY86-AS1 and KHDRBS2, which are closely related to the development of GBM, were identified by WGCNA and differential expression analysis. The Cancer Genome Atlas (TCGA) and the Chinese Glioma Genome Atlas (CGGA) databases were used to analyze the relationship between the expression of LY86-AS1 and KHDRBS2 and the prognosis of GBM patients. Multiple datasets were employed to analyze the correlation between the expression levels of LY86-AS1 and KHDRBS2 and its relationship with immune cell infiltration. Real-time quantitative PCR was used to verify the expression of LY86-AS1 and KHDRBS2 in GBM and normal brain tissues. The Human Protein Atlas (HPA) database was accessed to obtain the protein expression of KHDRBS2, and immunohistochemical staining was conducted to verify the protein expression of KHDRBS2. Results LY86-AS1 and KHDRBS2 were lowly expressed in GBM tissues and were closely related to the development of GBM, showing a significant positive correlation. Patients with low expression levels of LY86-AS1 and KHDRBS2 had a lower overall survival rate than those with high expression levels. LY86-AS1 was positively correlated with naive B cells, plasma cells, activated NK cells, M1 macrophages, activated mast cells and monocytes. KHDRBS2 was positively correlated with naive B cells, plasma cells, helper T cells, activated NK cells and monocytes. Conclusion The low expression levels of LY86-AS1 and KHDRBS2 in GBM, which is associated with poor prognosis, affect the tumor immune microenvironment and may serve as potential new biomarkers for the diagnosis of GBM and the prognosis assessment of patients.
